The Utility of Changes in Serum Levels of C-Terminal Telopeptide of Type I Collagen in Predicting Patient Response to Oral Monthly Ibandronate Therapy

Journal of Clinical Densitometry

Volumn 13, Issue 2, 2010, Pages 181-189

  Hochberg, Marc C ^a   Silverman, Stuart L ^b   Barr, Charles E ^c   Miller, Paul D ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Cedars Sinai/UCLA and OMC Clinical Research Center   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d University of Colorado Health Sciences Center   (United States)

Author keywords

Bisphosphonates; bone densitometry; bone turnover markers; ibandronate; osteoporosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS, POSTMENOPAUSAL; PREDICTIVE VALUE; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; TREATMENT OUTCOME; COLLAGEN TYPE I; PEPTIDES;

EID: 77951623035     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.01.007     Document Type: Article

References (36)

1. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 119 (2006) S25-31
2. Ravn P., Hosking D., Thompson D., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84 (1999) 2363-2368
3. Harris S.T., Gertz B.J., Genant H.K., et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76 (1993) 1399-1406
4. Ravn P., Clemmesen B., and Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24 (1999) 237-244
5. Ravn P., Thompson D.E., Ross P.D., and Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33 (2003) 150-158
6. Greenspan S.L., Parker R.A., Ferguson L., et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13 (1998) 1431-1438
7. Greenspan S.L., Rosen H.N., and Parker R.A. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 85 (2000) 3537-3540
8. Christgau S., Rosenquist C., Alexandersen P., et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44 (1998) 2290-2300
9. Rosen H.N., Moses A.C., Garber J., et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 66 (2000) 100-103
10. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
11. Reginster J.Y., Adami S., Lakatos P., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65 (2006) 654-661
12. Bjarnason N.H., Henriksen E.E., Alexandersen P., et al. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
13. Qvist P., Christgau S., Pedersen B.J., et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31 (2002) 57-61
14. Bonnick S.L., Johnston Jr. C.C., Kleerekoper M., et al. Importance of precision in bone density measurements. J Clin Densitom 4 (2001) 105-110
15. Sebba A.I., Bonnick S.L., Kagan R., et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20 (2004) 2031-2041
16. Chen Y.T., Miller P.D., Barrett-Connor E., et al. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int 18 (2007) 1287-1296
17. Girman C.J., Chandler J.M., Zimmerman S.I., et al. Prediction of fracture in nursing home residents. J Am Geriatr Soc 50 (2002) 1341-1347
18. Jin H., Lu Y., Harris S.T., et al. Classification algorithms for hip fracture prediction based on recursive partitioning methods. Med Decis Making 24 (2004) 386-398
19. Miller P.D., Barlas S., Brenneman S.K., et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164 (2004) 1113-1120
20. Quartararo M., Glasziou P., and Kerr C.B. Classification trees for decision making in long-term care. J Gerontol A Biol Sci Med Sci 50 (1995) M298-302
21. Miller P.D., Baran D.T., Bilezikian J.P., et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 2 (1999) 323-342
22. Bauer D.C., Garnero P., Bilezikian J.P., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91 (2006) 1370-1375
23. Chen P., Satterwhite J.H., Licata A.A., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005) 962-970
24. Rosen C.J., Chesnut III C.H., and Mallinak N.J. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82 (1997) 1904-1910
25. Kim S.W., Park D.J., Park K.S., et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52 (2005) 667-674
26. Looker A.C., Bauer D.C., Chesnut III C.H., et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11 (2000) 467-480
27. Akesson K., Kakonen S.M., Josefsson P.O., et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab 23 (2005) 30-35
28. Garnero P., Sornay-Rendu E., Chapuy M.C., and Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11 (1996) 337-349
29. Garnero P., Borel O., and Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47 (2001) 694-702
30. Zaidi M., Epstein S., and Friend K. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. Ann N Y Acad Sci 1068 (2006) 560-563
31. Greenspan S.L., Dresner-Pollak R., Parker R.A., et al. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 60 (1997) 419-423
32. Schlemmer A., Ravn P., Hassager C., and Christiansen C. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone 20 (1997) 63-67
33. Glover S.J., Garnero P., Naylor K., et al. Establishing a reference range for bone turnover markers in young, healthy women. Bone 42 (2008) 623-630
34. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
35. Gold D.T., and McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med 119 (2006) S32-37
36. Delmas P.D., Vrijens B., Eastell R., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92 (2007) 1296-1304